{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:40:30Z","timestamp":1790617230017,"version":"4.1.0"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007195","name":"University of Naples Federico II","doi-asserted-by":"publisher","award":["0016505"],"award-info":[{"award-number":["0016505"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"crossref","award":["RIS 3 \u2013 POR FSE CAMPANIA 2014\/2020"],"award-info":[{"award-number":["RIS 3 \u2013 POR FSE CAMPANIA 2014\/2020"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["17037"],"award-info":[{"award-number":["17037"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pennsylvania Department of Health for Sbarro Health Research Organization"},{"name":"Ken&Ann Douglas"},{"name":"Charitable Foundation Trust"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.neuropharm.2018.03.009","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T18:18:23Z","timestamp":1520533103000},"page":"126-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Huntingtin protein: A new option for fixing the Huntington's disease countdown clock"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8470-0789","authenticated-orcid":false,"given":"Marco","family":"Caterino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Squillaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-6911","authenticated-orcid":false,"given":"Daniela","family":"Montesarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosa A.B.","family":"Melone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.03.009_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/acs.biochem.6b00936","article-title":"Proteins containing expanded polyglutamine tracts and neurodegenerative disease","volume":"56","author":"Adegbuyiro","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib3","article-title":"A\u00a0novel inhibitor of Caspase-6 provides protection against mutant huntingtin toxicity","volume":"53","author":"Aharony","year":"2014","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib4","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/hmg\/ddv023","article-title":"A\u00a0Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits","volume":"24","author":"Aharony","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib5","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","article-title":"Phosphorylation of Threonine 3 implications for huntingtin aggregation and neurotoxicity","volume":"284","author":"Aiken","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ng1095-115","article-title":"HEAT repeats in the Huntington's disease protein","volume":"11","author":"Andrade","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JHD-160231","article-title":"Generation and characterization of knock-in mouse models expressing versions of huntingtin with either an N17 or a combined PolyQ and proline-rich region deletion","volume":"6","author":"Andre","year":"2017","journal-title":"J.\u00a0Huntingt. Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1469-1809.2006.00335.x","article-title":"The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset","volume":"71","author":"Andresen","year":"2007","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib10","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1523\/JNEUROSCI.1831-07.2007","article-title":"Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons","volume":"27","author":"Anne","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/bmc-2015-0001","article-title":"The emerging role of the first 17 amino acids of huntingtin in Huntington's disease","volume":"6","author":"Arndt","year":"2015","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib12","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","article-title":"Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing","volume":"29","author":"Aronin","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib15","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/hmg\/ddm217","article-title":"Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity","volume":"16","author":"Atwal","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib16","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2174\/138161212799958387","article-title":"Thrombin binding aptamer, more than a simple aptamer: chemically modified derivatives and biomedical applications","volume":"18","author":"Avino","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/jacs.6b10893","article-title":"Structure and dynamics of the huntingtin exon-1 N-terminus: a solution NMR perspective","volume":"139","author":"Baias","year":"2017","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/hmg\/ddu504","article-title":"Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease","volume":"24","author":"Barbaro","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib19","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1073\/pnas.1402215111","article-title":"Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A","volume":"111","author":"Bhat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jmb.2005.10.053","article-title":"Oligoproline effects on polyglutamine conformation and aggregation","volume":"355","author":"Bhattacharyya","year":"2006","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib21","doi-asserted-by":"crossref","first-page":"15400","DOI":"10.1073\/pnas.0501651102","article-title":"Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction","volume":"102","author":"Bhattacharyya","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bpj.2016.01.015","article-title":"Free-energy landscape of the amino-terminal fragment of huntingtin in aqueous solution","volume":"110","author":"Binette","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib23","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1093\/hmg\/ddx260","article-title":"Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity","volume":"26","author":"Branco-Santos","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib24","doi-asserted-by":"crossref","first-page":"31739","DOI":"10.1074\/jbc.M112.353839","article-title":"Structural features and domain organization of huntingtin fibrils","volume":"287","author":"Bugg","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib25","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.bbamem.2013.04.025","article-title":"Huntingtin disrupts lipid bilayers in a polyQ-length dependent manner","volume":"1828","author":"Burke","year":"2013","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib26","doi-asserted-by":"crossref","first-page":"14993","DOI":"10.1074\/jbc.M112.446237","article-title":"The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin","volume":"288","author":"Burke","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2018.03.009_bib208","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23021","article-title":"Inhibition of polyglutamine aggregation by SIMILAR huntingtin N-terminal sequences: prospective molecules for preclinical evaluation in Huntington's disease","volume":"108","author":"Burra","year":"2017","journal-title":"Biopolymers"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib28","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1073\/pnas.1301342110","article-title":"Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin","volume":"110","author":"Caron","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tcb.2009.01.005","article-title":"Huntingtin as an essential integrator of intracellular vesicular trafficking","volume":"19","author":"Caviston","year":"2009","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib30","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1073\/pnas.0610628104","article-title":"Huntingtin facilitates dynein\/dynactin-mediated vesicle transport","volume":"104","author":"Caviston","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpj.2014.11.1404","article-title":"Acetylation regulates the interaction of huntingtin with lipid membranes: implications for huntington disease","volume":"108","author":"Chaibva","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib32","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1021\/bi401619q","article-title":"Curvature enhances binding and aggregation of huntingtin at lipid membranes","volume":"53","author":"Chaibva","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bpj.2016.06.018","article-title":"Acetylation within the first 17 residues of huntingtin exon 1 alters aggregation and lipid binding","volume":"111","author":"Chaibva","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib34","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/mt.2015.157","article-title":"Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in\u00a0vitro and in a yeast model of Huntington's disease","volume":"23","author":"Chaudhary","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib35","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1073\/pnas.1702237114","article-title":"Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/JHD-160207","article-title":"N-terminal fragments of huntingtin longer than residue 170 form visible aggregates independently to polyglutamine expansion","volume":"6","author":"Chen","year":"2017","journal-title":"J.\u00a0Huntingt. Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jmbi.2001.4850","article-title":"Polyglutamine aggregation behavior in\u00a0vitro supports a recruitment mechanism of cytotoxicity","volume":"311","author":"Chen","year":"2001","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib38","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1073\/pnas.182276099","article-title":"Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation","volume":"99","author":"Chen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/hum.1994.5.5-595","article-title":"Intracellular antibodies as a new class of therapeutic molecules for gene therapy","volume":"5","author":"Chen","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib40","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1002\/anie.201611750","article-title":"Mutant Exon1 huntingtin aggregation is regulated by T3 phosphorylation-induced structural changes and crosstalk between T3 phosphorylation and acetylation at K6","volume":"56","author":"Chiki","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib41","article-title":"Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody (vol. 101, pg 17616, 2004)","volume":"102","author":"Colby","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib42","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1460-9568.2005.03985.x","article-title":"Akt is altered in an animal model of Huntington's disease and in patients","volume":"21","author":"Colin","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib43","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.1073\/pnas.1320626110","article-title":"Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation","volume":"110","author":"Crick","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-05336-7","article-title":"Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models","volume":"7","author":"Daldin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib45","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.bpj.2009.07.062","article-title":"Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect","volume":"97","author":"Darnell","year":"2009","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","article-title":"Huntington disease: pathogenesis and treatment","volume":"33","author":"Dayalu","year":"2015","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib47","doi-asserted-by":"crossref","first-page":"35608","DOI":"10.1074\/jbc.M605558200","article-title":"Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast","volume":"281","author":"Dehay","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib48","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/asia.201700374","article-title":"Enzymatic synthesis of 7,5-bicyclo-DNA oligonucleotides","volume":"12","author":"Diafa","year":"2017","journal-title":"Chemistry-an Asian Journal"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","article-title":"The world of protein acetylation","volume":"1864","author":"Drazic","year":"2016","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib50","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1073\/pnas.0604547103","article-title":"Flanking sequences profoundly alter polyglutamine toxicity in yeast","volume":"103","author":"Duennwald","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib52","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"El-Daher","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib53","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","article-title":"Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records","volume":"84","author":"Evans","year":"2013","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12640-017-9766-1","article-title":"Huntington's disease and mitochondria","volume":"32","author":"Farshbaf","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk","volume":"29","author":"Fisher","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib56","first-page":"759","article-title":"Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs","volume":"63","author":"Fiszer","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112262","article-title":"Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy","volume":"9","author":"Fodale","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib58","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1074\/jbc.M401267200","article-title":"Inhibition of calpain cleavage of huntingtin reduces toxicity - accumulation of calpain\/caspase fragments in the nucleus","volume":"279","author":"Gafni","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib59","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1523\/JNEUROSCI.6379-11.2012","article-title":"Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment","volume":"32","author":"Gafni","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib60","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib61","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.str.2006.09.014","article-title":"Structural insights into the specific binding of huntingtin proline-rich region with the SH3 and WW domains","volume":"14","author":"Gao","year":"2006","journal-title":"Structure"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib62","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4161\/rna.26706","article-title":"Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis","volume":"10","author":"Gipson","year":"2013","journal-title":"RNA Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","article-title":"Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis","volume":"67","author":"Godin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib64","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1523\/JNEUROSCI.2071-10.2010","article-title":"Cleavage at the 586 amino acid Caspase-6 site in mutant huntingtin influences Caspase-6 activation in\u00a0vivo","volume":"30","author":"Graham","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.2010.222570.4","article-title":"Caspase 6 resistant mutant huntingtin does not rescue the toxic effects of caspase cleavable mutant huntingtin in\u00a0vivo","volume":"81","author":"Graham","year":"2010","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib66","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib67","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1073\/pnas.0914073107","article-title":"PR65, the HEAT-repeat scaffold of phosphatase PP2A, is an elastic connector that links force and catalysis","volume":"107","author":"Grinthal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib68","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature25502","article-title":"The cryo-electron microscopy structure of huntingtin","volume":"555","author":"Guo","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","article-title":"The hunt for huntingtin function: interaction partners tell many different stories","volume":"28","author":"Harjes","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bpc.2013.11.008","article-title":"Length-dependent conformational transitions of polyglutamine repeats as molecular origin of fibril initiation","volume":"185","author":"Heck","year":"2014","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/brainsci4010091","article-title":"Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion","volume":"4","author":"Hoffner","year":"2014","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib73","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/jcs.115.5.941","article-title":"Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease","volume":"115","author":"Hoffner","year":"2002","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib74","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.1523\/JNEUROSCI.1418-17.2017","article-title":"Mutant huntingtin inhibits alpha B-Crystallin expression","volume":"37","author":"Hong","year":"2017","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib75","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/bi501010q","article-title":"Polyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance","volume":"53","author":"Hoop","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib76","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1073\/pnas.1521933113","article-title":"Huntingtin exon 1 fibrils feature an interdigitated beta-hairpin-based polyglutamine core","volume":"113","author":"Hoop","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib77","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3892\/etm.2016.3566","article-title":"Huntington's disease: molecular basis of pathology and status of current therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib78","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jmb.2013.12.028","article-title":"Identification of novel alternative splicing events in the huntingtin gene and assessment of the functional consequences using structural protein homology modelling","volume":"426","author":"Hughes","year":"2014","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib79","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib80","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tem.2015.09.013","article-title":"Protein phosphorylation: a major switch mechanism for metabolic regulation","volume":"26","author":"Humphrey","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib81","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1021\/acs.biochem.7b00138","article-title":"Formation and structure of wild type huntingtin Exon-1 fibrils","volume":"56","author":"Isas","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib82","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1021\/acs.biochem.5b00281","article-title":"Solid-state nuclear magnetic resonance on the static and dynamic domains of huntingtin Exon-1 fibrils","volume":"54","author":"Isas","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib83","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ydbio.2014.04.005","article-title":"Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells","volume":"391","author":"Ismailoglu","year":"2014","journal-title":"Dev. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib84","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jmb.2011.12.010","article-title":"Slow amyloid nucleation via alpha-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments","volume":"415","author":"Jayaraman","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib85","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jmb.2011.12.010","article-title":"Slow amyloid nucleation via alpha-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments","volume":"415","author":"Jayaraman","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib86","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1021\/bi3000929","article-title":"Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/tra.12453","article-title":"Polyglutamine toxicity in yeast uncovers phenotypic variations between different fluorescent protein fusions","volume":"18","author":"Jiang","year":"2017","journal-title":"Traffic"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib89","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2015.00001","article-title":"Detection of ubiquitinated huntingtin species in intracellular aggregates","volume":"8","author":"Juenemann","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib91","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1021\/jacs.7b00838","article-title":"Emerging beta-sheet rich conformations in supercompact huntingtin Exon-1 mutant structures","volume":"139","author":"Kang","year":"2017","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/nsmb.1992","article-title":"Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent","volume":"18","author":"Kar","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib93","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jmb.2009.01.032","article-title":"The predicted structure of the headpiece of the huntingtin protein and its implications on huntingtin aggregation","volume":"388","author":"Kelley","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib94","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbamcr.2008.12.004","article-title":"Self-activation of Caspase-6 in\u00a0vitro and in\u00a0vivo: caspase-6 activation does not induce cell death in HEK293T cells","volume":"1793","author":"Klaiman","year":"2009","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib95","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1021\/bi501066q","article-title":"Effect of helical flanking sequences on the morphology of polyglutamine-containing fibrils","volume":"53","author":"Kokona","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib96","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1021\/bi500449a","article-title":"Role of the coiled-coil structural motif in polyglutamine aggregation","volume":"53","author":"Kokona","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib97","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/cr.2008.5","article-title":"Features of trinucleotide repeat instability in\u00a0vivo","volume":"18","author":"Kovtun","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nm0110-32","article-title":"Huntington's disease: tagged for clearance","volume":"16","author":"Krainc","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005727","article-title":"Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity","volume":"4","author":"Kvam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzq022","article-title":"Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm","volume":"23","author":"Kvam","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib101","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/4fd085bfc9973","article-title":"Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease","volume":"4","author":"Landles","year":"2012","journal-title":"PLoS Curr"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0033583506004422","article-title":"Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?","volume":"39","author":"Lashuel","year":"2006","journal-title":"Q.\u00a0Rev. Biophys."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib104","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1074\/jbc.M109.093708","article-title":"Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in\u00a0vitro and in\u00a0vivo","volume":"285","author":"Legleiter","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nbd.2012.11.016","article-title":"Phosphodiesterase 10A (PDE10A) localization in the R6\/2 mouse model of Huntington's disease","volume":"52","author":"Leuti","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib106","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1074\/jbc.M511007200","article-title":"Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein","volume":"281","author":"Li","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib107","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-6-37","article-title":"Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons","volume":"6","author":"Liang","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15462","article-title":"Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine core","volume":"8","author":"Lin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib109","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/15476286.2016.1236173","article-title":"In\u00a0vitro evolution of chemically-modified nucleic acid aptamers: pros and cons, and comprehensive selection strategies","volume":"13","author":"Lipi","year":"2016","journal-title":"RNA Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib110","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A\u00a0novel gene containing a trinucleotide repeat that is expanded and unstable on huntingtons-disease chromosomes","volume":"72","author":"Macdonald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib111","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cellsig.2017.02.023","article-title":"Huntingtin-associated protein-1 (HAP1) regulates endocytosis and interacts with multiple trafficking-related proteins","volume":"35","author":"Mackenzie","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib112","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/hmg\/dds554","article-title":"The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal","volume":"22","author":"Maiuri","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib113","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib114","first-page":"395","article-title":"Huntingtin: here, there, everywhere!","volume":"2","author":"Marques Sousa","year":"2013","journal-title":"J\u00a0Huntingtons Dis"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib115","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1093\/hmg\/ddu027","article-title":"Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin","volume":"23","author":"Martin","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib116","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/nrn2276","article-title":"Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction","volume":"8","author":"Martin","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib117","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbadis.2012.09.001","article-title":"Mutant huntingtin regulates EGF receptor fate in non-neuronal cells lacking wild-type protein","volume":"1832","author":"Melone","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib118","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1389450053344975","article-title":"Huntington's disease: new frontiers for molecular and cell therapy","volume":"6","author":"Melone","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib119","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1523\/JNEUROSCI.21-06-01830.2001","article-title":"Tissue-specific proteolysis of huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum","volume":"21","author":"Mende-Mueller","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00249-014-0966-9","article-title":"Investigation of membrane penetration depth and interactions of the amino-terminal domain of huntingtin: refined analysis by tryptophan fluorescence measurement","volume":"43","author":"Michalek","year":"2014","journal-title":"European Biophysics Journal with Biophysics Letters"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib121","doi-asserted-by":"crossref","first-page":"362a","DOI":"10.1016\/j.bpj.2012.11.2014","article-title":"Membrane structure and interactions of the amphipathic N-Terminus of huntingtin","volume":"104","author":"Michalek","year":"2013","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib122","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.bpj.2013.06.030","article-title":"Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach","volume":"105","author":"Michalek","year":"2013","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib123","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1021\/bi301325q","article-title":"Membrane interactions of the amphipathic amino terminus of huntingtin","volume":"52","author":"Michalek","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio0312-318a","article-title":"Identifying polyglutamine protein species in situ that best predict neurodegeneration (vol. 7, pg 925, 2011)","volume":"8","author":"Miller","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib125","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jmb.2011.12.011","article-title":"Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting alpha-helix-rich oligomeric intermediates","volume":"415","author":"Mishra","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JHD-150151","article-title":"Huntingtin exists as multiple splice forms in human brain","volume":"4","author":"Mort","year":"2015","journal-title":"J.\u00a0Huntingt. Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib127","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2012.07.011","article-title":"Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer","volume":"136","author":"Musumeci","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib128","doi-asserted-by":"crossref","first-page":"17511","DOI":"10.3390\/molecules200917511","article-title":"G-quadruplex forming oligonucleotides as anti-HIV agents","volume":"20","author":"Musumeci","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib129","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/jp407900c","article-title":"The effects of flanking sequences in the interaction of polyglutamine peptides with a membrane bilayer","volume":"118","author":"Nagarajan","year":"2014","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib130","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1101\/gr.147400","article-title":"HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions","volume":"10","author":"Neuwald","year":"2000","journal-title":"Genome Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081683","article-title":"Chemical modifications of nucleic acid aptamers for therapeutic purposes","volume":"18","author":"Ni","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib132","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1074\/jbc.M111.252577","article-title":"Identification of novel potentially toxic oligomers formed in\u00a0vitro from mammalian-derived expanded huntingtin Exon-1 protein","volume":"287","author":"Nucifora","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib133","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1007\/s12035-016-0337-x","article-title":"Huntingtin polyQ mutation impairs the 17 beta-estradiol\/neuroglobin pathway devoted to neuron survival","volume":"54","author":"Nuzzo","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib134","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.celrep.2013.06.034","article-title":"SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation","volume":"4","author":"O'Rourke","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00077","article-title":"Ubiquitin-proteasome system involvement in Huntington's disease","volume":"7","author":"Ortega","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib136","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/nat.2015.0547","article-title":"Allele-selective inhibition of mutant huntingtin with 2-thio- and C5-Triazolylphenyl-Deoxythymidine-Modified antisense oligonucleotides","volume":"25","author":"Ostergaard","year":"2015","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib137","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000304","article-title":"Detection of alpha-rod protein repeats using a neural network and application to huntingtin","volume":"5","author":"Palidwor","year":"2009","journal-title":"PLoS Comput. Biol."},{"issue":"7","key":"10.1016\/j.neuropharm.2018.03.009_bib139","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1074\/jbc.M117.813667","article-title":"The 17-residue-long N terminus in huntingtin controls step-wise aggregation in solution and on membranes via different mechanisms","volume":"293","author":"Pandey","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib140","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1523\/JNEUROSCI.3706-05.2006","article-title":"Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421","volume":"26","author":"Pardo","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1385\/JMN:24:2:257","article-title":"Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine","volume":"24","author":"Parekh-Olmedo","year":"2004","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib142","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2014-309032.29","article-title":"Development of aptamers for the specific detection of the amino-terminal region of the huntingtin protein","volume":"85","author":"Perandones","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib143","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00033-3","article-title":"The ATRs, ATMs, and TORs are giant HEAT repeat proteins","volume":"112","author":"Perry","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib144","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1073\/pnas.91.12.5355","article-title":"Glutamine repeats as polar zippers - their possible role in inherited neurodegenerative diseases","volume":"91","author":"Perutz","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib145","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.bbagen.2016.11.027","article-title":"G-quadruplex-based aptamers against protein targets in therapy and diagnostics","volume":"1861","author":"Platella","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib146","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/brain\/awp006","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","volume":"132","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib147","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1134\/S002689331704015X","article-title":"Protein-protein interactions of huntingtin in the Hippocampus","volume":"51","author":"Proskura","year":"2017","journal-title":"Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib148","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.0953-816X.2003.03131.x","article-title":"The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin","volume":"19","author":"Rangone","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib149","doi-asserted-by":"crossref","first-page":"10855","DOI":"10.1074\/jbc.M804813200","article-title":"Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells","volume":"284","author":"Ratovitski","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib150","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1021\/acs.jproteome.6b00991","article-title":"Post-translational modifications (PTMs), identified on endogenous huntingtin, cluster within proteolytic domains between HEAT repeats","volume":"16","author":"Ratovitski","year":"2017","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib151","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/mds.21988","article-title":"The relationship between CAG repeat length and clinical progression in Huntington's disease","volume":"23","author":"Ravina","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib152","article-title":"The relationship between CAG repeat length and progression in Huntington's disease","volume":"62","author":"Ravina","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib153","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1007\/s12035-016-0120-z","article-title":"Modulation of molecular chaperones in Huntington's disease and other polyglutamine disorders","volume":"54","author":"Reis","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib154","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.febslet.2011.08.036","article-title":"Conformations of the Huntingtin N-term in aqueous solution from atomistic simulations","volume":"585","author":"Rossetti","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/ncb3101","article-title":"Huntingtin functions as a scaffold for selective macroautophagy","volume":"17","author":"Rui","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib156","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1042\/BJ20110679","article-title":"Palmitoylation and trafficking of GAD65 are impaired in a cellular model of Huntington's disease","volume":"442","author":"Rush","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127687","article-title":"Discovery of novel isoforms of huntingtin reveals a new hominid-specific exon","volume":"10","author":"Ruzo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib158","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1021\/bi500300c","article-title":"Aggregation behavior of chemically synthesized, full-length huntingtin Exon1","volume":"53","author":"Sahoo","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib159","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/BST20140242","article-title":"Aberrant palmitoylation in Huntington disease","volume":"43","author":"Sanders","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib160","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib161","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib162","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib163","doi-asserted-by":"crossref","first-page":"23686","DOI":"10.1074\/jbc.M513507200","article-title":"Huntingtin phosphorylation sites mapped by mass spectrometry - modulation of cleavage and toxicity","volume":"281","author":"Schilling","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib164","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.05.024","article-title":"Network organization of the huntingtin proteomic interactome in mammalian brain","volume":"75","author":"Shirasaki","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2017.03.015","article-title":"N-type Ca2+ channels are affected by full-length mutant huntingtin expression in a mouse model of Huntington's disease","volume":"55","author":"Silva","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib166","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1021\/ja110715f","article-title":"The aggregation-enhancing huntingtin N-Terminus is helical in amyloid fibrils","volume":"133","author":"Sivanandam","year":"2011","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib167","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-7-65","article-title":"Short G-rich oligonucleotides as a potential therapeutic for huntington's disease","volume":"7","author":"Skogen","year":"2006","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib168","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"JNEN (J. Neuropathol. Exp. Neurol.)"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016676","article-title":"Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1","volume":"6","author":"Southwell","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib170","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib171","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib172","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bcp.12987","article-title":"Therapeutic nucleic acids: current clinical status","volume":"82","author":"Sridharan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib173","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1092194","article-title":"SUMO modification of Huntingtin and Huntington's disease pathology","volume":"304","author":"Steffan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib174","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib175","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nsmb.1700","article-title":"The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation","volume":"16","author":"Tam","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib176","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/molbev\/msm258","article-title":"Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin","volume":"25","author":"Tartari","year":"2008","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050750","article-title":"Analysis of proteolytic processes and enzymatic activities in the generation of huntingtin N-Terminal fragments in an HEK293 cell model","volume":"7","author":"Tebbenkamp","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib178","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nsmb.1570","article-title":"Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism","volume":"16","author":"Thakur","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib179","doi-asserted-by":"crossref","first-page":"17014","DOI":"10.1073\/pnas.252523899","article-title":"Mutational analysis of the structural organization of polyglutamine aggregates","volume":"99","author":"Thakur","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib180","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib181","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1074\/jbc.M113.523696","article-title":"A\u00a0large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease","volume":"289","author":"Tourette","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib182","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib183","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/med.21394","article-title":"The role of cathepsin D in the pathogenesis of human neurodegenerative disorders","volume":"36","author":"Vidoni","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib184","article-title":"Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation","author":"Vidoni","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib185","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11184","article-title":"Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function","volume":"5","author":"Vijayvargia","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib186","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib187","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.2174\/092986711797189565","article-title":"Improving the stability of aptamers by chemical modification","volume":"18","author":"Wang","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib188","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12264-010-1118-6","article-title":"The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease","volume":"26","author":"Wang","year":"2010","journal-title":"Neuroscience Bulletin"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib189","article-title":"The hunt for Huntingtin function: interaction partners and the pathogenesis of Huntington's disease","volume":"94","author":"Wanker","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib190","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddn139","article-title":"Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus","volume":"17","author":"Warby","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088284","article-title":"Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity","volume":"9","author":"Watkin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib192","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","article-title":"Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease","volume":"22","author":"Wellington","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib193","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","article-title":"Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract","volume":"273","author":"Wellington","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib194","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jmb.2012.01.030","article-title":"Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence","volume":"421","author":"Wetzel","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib195","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib196","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib197","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jmb.2009.12.017","article-title":"Modulation of polyglutamine conformations and dimer formation by the N-Terminus of huntingtin","volume":"396","author":"Williamson","year":"2010","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib198","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1523\/JNEUROSCI.1969-16.2017","article-title":"Aptamers as valuable molecular tools in neurosciences","volume":"37","author":"Wolter","year":"2017","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib199","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nbd.2014.12.030","article-title":"Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice","volume":"76","author":"Wong","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib200","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nn1702","article-title":"Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function","volume":"9","author":"Yanai","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib201","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jnr.22210","article-title":"A\u00a0stable g-quartet binds to a huntingtin protein fragment containing expanded polyglutamine tracks","volume":"88","author":"Yerkes","year":"2010","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib202","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1093\/nar\/gkx111","article-title":"CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression","volume":"45","author":"Zaghloul","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib203","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1021\/acs.jpcb.7b01476","article-title":"Molecular mechanism of stabilizing the helical structure of huntingtin N17 in a micellar environment","volume":"121","author":"Zhang","year":"2017","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib204","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1242\/dmm.003376","article-title":"Hunting for the function of huntingtin","volume":"2","author":"Zheng","year":"2009","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/j.neuropharm.2018.03.009_bib205","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1074\/jbc.M112.413575","article-title":"An N-terminal nuclear export signal regulates trafficking and aggregation of huntingtin (htt) protein exon 1","volume":"288","author":"Zheng","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib206","article-title":"Aptamers as targeted therapeutics: current potential and challenges (vol. 16, pg 181, 2017)","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.03.009_bib207","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818301102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818301102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T17:39:17Z","timestamp":1660585157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818301102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":208,"alternative-id":["S0028390818301102"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.03.009","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Huntingtin protein: A new option for fixing the Huntington's disease countdown clock","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}